Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
admin 21st June 2018 Uncategorised 0The FDA approved a label expansion for Cinryze that makes it available for children as young as 6 with HAE. That could help Shire fend off an all-out attack from rival CSL, which has already stolen market share from its rival.
More: Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Source: fierce